UnitedHealth Group experienced an unexpected surge in medical costs during fiscal 2025, resulting in a 45% decline in its share price over the year. The company’s medical loss ratio expanded by 3.2 percentage points to 85.7%, driven primarily by higher hospitalization rates and specialty drug expenditures. This margin erosion reduced operating income to $18.4 billion, down from $27.1 billion in 2024, marking the steepest annual drop in profitability in over a decade.

Under CEO Stephen Hemsley, appointed in March 2025, UnitedHealth has embarked on an aggressive repricing initiative aimed at restoring underwriting margins. The program targets a 4% increase in average premiums for commercial members and a 2.5% uptick in Medicare Advantage bids for plan year 2026. Management has signaled a shift in focus from membership growth—where enrollment grew just 1.8% in 2025—to profit per member, forecasting a margin improvement of 150 basis points by year-end 2026.

UnitedHealth’s vertically integrated model—combining insurance, pharmacy benefit management and provider services—offers scale benefits that could accelerate margin recovery. The company processes over 300 million medical and pharmacy claims annually and leverages Predictive Health Analytics across its 45,000 primary care physicians. However, execution risks persist: management warns of potential attrition among price-sensitive commercial members, ongoing funding cuts to Medicare Advantage programs projected to total $9 billion over the next three years, and an active Department of Justice investigation into alleged network steering practices. Investors will be closely watching Q4 earnings guidance, due January 27, for updated margin targets and membership trends.